GAO Report: Manufacturer Discounts in the 340B Program Offer Benefits, But Federal Oversight Needs Improvement

Thirteen of the 29 covered entities we interviewed reported that they generated 340B program revenue that exceeded drug-related costs, which includes the costs of purchasing and dispensing drugs.